Skip to content
You can now search across every topic, entity and event.What's new
Pandemics and Biosecurity
7MAY

FAO costs drug-resistance inaction at $318bn

2 min read
15:24UTC

The FAO put a price on antimicrobial resistance on 3 June, projecting $318bn in cumulative livestock losses by 2040, about six times the cost of acting now.

ScienceDeveloping
Key takeaway

Pricing drug resistance as $318bn in lost production reaches ministries a death toll never moved.

The Food and Agriculture Organization (FAO), the UN's Rome-based agency for food and farming, put a price on inaction over AMR (antimicrobial resistance, the process by which bacteria stop responding to the drugs meant to kill them) on 3 June. Its report projects global antimicrobial use in livestock rising 30% by 2040 against a 2019 baseline, and cumulative livestock production losses reaching $318bn by 2040 under a high-resistance scenario 1. That $318bn runs about six times the cost of acting now.

May's adoption of the WHO Global Action Plan on AMR set a mortality target, a 10% cut in bacterial AMR deaths by 2030. FAO has now attached a balance-sheet figure to the alternative, routing the same problem through food-security economics to reach an audience that a death toll did not. The 6:1 inaction-to-action ratio is the lever, reframing mitigation spending as loss avoidance rather than public-health cost.

Cheap antibiotics keep crowded herds productive, so use climbs with demand for meat, and resistance follows the use, an unremarkable chain that the $318bn figure now prices. Pricing the loss in production rather than deaths is how the issue reaches the agriculture and finance ministries that control the antibiotics and that a public-health framing never reached.

Deep Analysis

In plain English

Farmers use antibiotics to keep livestock healthy and speed up animal growth. When antibiotics are used too frequently, bacteria evolve to resist them, making those drugs less effective for both animals and humans over time. This is called antimicrobial resistance, or AMR. FAO, the UN's food and agriculture body, published a report on 3 June estimating that unchecked AMR will cost the farming industry $318 billion in lost livestock production by 2040, as animals die from infections that should be treatable. Preventing that outcome would cost around one-sixth as much. The report argues that tackling antibiotic overuse in farming serves both economic and public health goals.

Deep Analysis
Root Causes

The projected 30% rise in livestock antimicrobial use to 2040 reflects a structural dependency: antibiotic prophylaxis compensates for suboptimal biosecurity in intensive production systems. The economic incentive structure rewards volume and speed of production over herd health investment, particularly in markets where veterinary drug regulation is weak or enforcement is absent.

The WHO GAP-AMR 2026-2036 , adopted 23 May, sets a 10% reduction target in AMR-attributable deaths by 2030 , a human-health metric. The FAO report reframes AMR as a food-security and economic threat independent of that metric, addressing a different political constituency: agriculture ministries and development finance institutions that do not engage with WHO's public-health framing.

What could happen next?
  • Consequence

    FAO's $318bn figure provides an economic mandate for agriculture ministries to engage with the WHO GAP-AMR 2026-2036 (ID:3599) framework , translating a public-health target into a production-economics argument that reaches beyond health ministry budgets.

  • Risk

    The 30% projected rise in livestock antimicrobial use by 2040 is concentrated in regions with limited veterinary drug regulatory capacity, meaning the economic cost will fall disproportionately on small-scale farmers in lower-income countries who have the least ability to absorb it.

Sources:FAO
First Reported In

Update #6 · Ebola outbreak gets an R0, and a fork

FAO· 9 Jun 2026
Read original
Different Perspectives
Germany (evacuation recipient)
Germany (evacuation recipient)
Germany received the Bundibugyo outbreak's third international medical evacuation on 13 July, a US humanitarian worker infected in Bunia on 10 July. The evacuation, following a French doctor's 24 June departure and May's first US case, tests whether isolation and biocontainment protocols scale beyond DR Congo's own borders.
Pennsylvania Department of Public Health
Pennsylvania Department of Public Health
PDPH retested and retracted a false-positive measles wastewater signal on 6 July, then confirmed and publicised a real airport exposure from 4 July, with commissioner Palak Raval-Nelson stressing there is no broad threat to the general public. The national count, 2,231 cases across 42 states by 9 July, is on pace to beat 2025's 2,289-case record before September.
World Health Organization
World Health Organization
WHO published its first dedicated Blueprint on fungal disease and antifungal resistance on 1 July, estimating more than 300 million people suffer serious fungal disease annually. The Blueprint names the gap in WHO's own AMR strategy rather than waiting for an external audit to force the admission.
Africa CDC
Africa CDC
Africa CDC issued a formal 11 July appeal for responder protection, training and psychosocial support after health-worker infections tripled from 34 to 112 in a month. The appeal repeats June's unmet call for a rapid Bundibugyo diagnostic test, showing the ask has shifted from tools to basic safety and pay.
Front-line health workers, Ituri Province
Front-line health workers, Ituri Province
Health workers in Ituri Province walked off the job or threatened to strike over unpaid hazard pay and delayed salaries, even as responder infections tripled to 112 with 35 dead. Their absence narrows the isolation workforce the CDC's model says must reach 70% coverage to avoid a 20,000-case worst case.
ECDC
ECDC
ECDC co-published the isolation and contact-tracing figures behind WHO's DON612, tracking Ituri's isolation rate rising from 35 to 44 percent while still rating EU/EEA import risk as very low. Brussels backs the WHO line against travel restrictions, the position France's own contact-tracing response, not the US entry ban, actually validated.